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MitochondriaSkeletal muscle of insulin resistant individuals is characterized by lower fasting lipid oxidation and reduced
ability to switch between lipid and glucose oxidation. The purpose of the present study was to examine if
chronic hyperglycemia would impair metabolic switching of myotubes. Human myotubes were treated with
or without chronic hyperglycemia (20 mmol/l glucose for 4 days), and metabolism of [14C]oleic acid (OA) and
[14C]glucose was studied. Myotubes exposed to chronic hyperglycemia showed a signiﬁcantly reduced OA
uptake and oxidation to CO2, whereas acid-soluble metabolites were increased compared to normoglycemic
cells (5.5 mmol/l glucose). Glucose suppressibility, the ability of acute glucose (5 mmol/l) to suppress lipid
oxidation, was 50% in normoglycemic cells and reduced to 21% by hyperglycemia. Adaptability, the capacity to
increase lipid oxidation with increasing fatty acid availability, was not affected by hyperglycemia. Glucose
uptake and oxidation were reduced by about 40% after hyperglycemia, and oxidation of glucose in presence of
mitochondrial uncouplers showed that net and maximal oxidative capacities were signiﬁcantly reduced.
Hyperglycemia also abolished insulin-stimulated glucose uptake. Moreover, ATP concentration was reduced
by 25% after hyperglycemia. However, none of the measured mitochondrial genes were downregulated nor
was mitochondrial DNA content. Microarray and real-time RT-PCR showed that no genes were signiﬁcantly
regulated by chronic hyperglycemia. Addition of chronic lactate reduced both glucose and OA oxidation to the
same extent as hyperglycemia. In conclusion, chronic hyperglycemia reduced substrate oxidation in skeletal
muscle cells and impaired metabolic switching. The effect is most likely due to an induced mitochondrial
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Metabolic ﬂexibility is the capacity of the body to switch between
lipid oxidation in the fasting state to carbohydrate oxidation in the fed
state and vice versa, i.e. the capacity to adjust fuel consumption
according to availability [1]. Insulin resistance and type 2 diabetes
(T2D) have been associated with impaired ability to switch between
lipid and glucose oxidation [2,3], and it has been postulated that this
impaired metabolic switching is an intrinsic property of skeletal
muscle [4]. Ukropcova et al. [4] showed that the metabolic phenotype
of the donor was maintained in myotube cultures after removal of in
vivo neuroendocrine factors. However, metabolic ﬂexibility in vivo has
been shown to improve by weight loss [3], indicating that lifestyle
factors can affect metabolic ﬂexibility. We recently showed that
treatment with n-3 fatty acids improved metabolic switching of
myotubes [5]. Whether exposure to chronic hyperglycemia affects
metabolic ﬂexibility of skeletal muscle is at present unknown.
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dietary factors on development of intramuscular lipid accumulation
and insulin resistance. Skeletal muscle of obese and insulin-resistant
subjects is characterized by increased intramyocellular lipids (IMCL)
and reduced mitochondrial oxidative capacity [6,7]. We have
previously shown that myotubes from type 2 diabetic subjects have
reduced fatty acid oxidation after culturing in a non-diabetic
environment, implying a genetic defect [8]. Experiments in rats
conﬁrmed that there is an inherited connection between oxidative
capacity and a diabetic phenotype, as rats bred to obtain low aerobic
capacity were insulin resistant and displayed a diabetic metabolic
proﬁle [9]. These animals also expressed reduced level of several
proteins involved in mitochondrial biogenesis, suggesting a genetic
association between mitochondrial dysfunction and insulin resis-
tance. Several studies have shown reduced mitochondrial content
and/or mitochondrial dysfunction in skeletal muscle of T2D subjects
[10–12]. There is substantial support for the hypothesis that reduced
oxidative capacity might be the fundamental cause of IMCL accumu-
lation and insulin resistance [11,13]. However, the possibility that
mitochondrial dysfunction rather is the consequence of insulin
resistance cannot be excluded.
In rat, chronic glucose infusion induced insulin resistance in
skeletal muscle concurrent with increased triacylglycerol (TAG),
malonyl-CoA and long-chain fatty acyl-CoA (LCA-CoA) levels in
muscle [14]. Lipid intermediates, such as fatty acyl-CoA, ceramides
and diacylglycerol, are linked to muscle insulin resistance both in vivo
and in several in vitro models [15]. Glucose oversupply has also been
associated with a range of metabolic changes, such as increased
lactate production [16,17], and it has been shown that diabetic and
obese patients have increased plasma lactate levels [18,19]. The role of
lactate is not known, but it is most likely more complex than being a
simple waste product of metabolism (reviewed in [20,21]). It has been
hypothesized that lactate is a signaling molecule directing metabolic
activity. In muscle, lactate inhibits 6-phosphofructo-1-kinase and
consequently decreases glucose consumption [22].
Chronic hyperglycemia (HG) has been shown to contribute to
insulin resistance in skeletal muscle [23]. The mechanism, however,
by which HG induces insulin resistance is not clear. We have
previously shown that treatment of human myotubes with chronic
HG reduced acute glucose uptake and glycogen synthesis. This
reduction accompanied accumulation of TAG in the cells, an increased
de novo lipogenesis and increased acyl-CoA:1.2-diacylglycerol acyl-
transferase (DGAT) activity, whereas total cell content of glycogen
was unchanged [24]. The effect of HG was maximal after 4 days and
reversible, at least when it came to glycogen synthesis [24]. Exposure
of 3T3-L1 adipocytes to HG has been found to induce insulin
resistance and loss of mitochondrial membrane potential [25].
Moreover, mitochondria became smaller and more compact, whereas
mitochondrial DNA was unaffected by HG [25], indicating that HG can
induce mitochondrial dysfunction. Therefore, we hypothesized that
exposure to chronic HG induces some kind of mitochondrial
dysfunction leading to impaired metabolic switching of myotubes.
2. Experimental
2.1. Materials
L-Glutamine, penicillin/streptomycin (10,000 IE/10 mg/ml),
HEPES, amphotericin B, L-carnitine, sodium L-lactate, dinitrophenol
(DNP), carbonylcyanide-4-triﬂuoromethoxyphenylhydrazone
(FCCP), oligomycin and extracellular matrix (ECM) gel were from
Sigma (St. Louis, MO, USA). Dulbecco's Modiﬁed Eagle's Medium low
glucose (DMEM), DMEM-Glutamax, foetal calf serum (FCS), Dulbec-
co's Phosphate Buffered Saline (DPBS) and trypsin/EDTA (0.05%) were
from Gibco/Invitrogen (Grand Island, NY, USA). Ultroser G was from
Pall Corporation (St-Germain-en-Laye Cedex, France) and lactic acidwas from Apotekproduksjon AS (Oslo, Norway). D-[6-14C]glucose
(56 mCi/mmol–2.1 GBq/mmol), D-[1-14C]glucose (54 mCi/mmol–
2.0 GBq/mmol), D-[14C(U)]glucose (10 mCi/mmol–0.37 GBq/mmol),
[1-14C]oleic acid (53 mCi/mmol–2.0 GBq/mmol) and L-[14C(U)]leu-
cine (318 mCi/mmol–11.766 GBq/mmol) were provided by either by
American Radiolabeled Chemicals Inc. (St. Louis, MO, USA) or by NEN
Radiochemicals, PerkinElmer (Boston, MA, USA). Insulin Actrapid®
was fromNovo Nordisk (Bagsvaerd, Denmark). The antibodies against
AMPK (#2532), phosphorylated AMPK (Thr172, #2531), ACC (#3662)
and phosphorylated ACC (Ser79, #3661) were from Cell Signaling
Technology (Beverly, MA, US). The pyruvate dehydrogenase kinase
(PDHK) inhibitor AZD7545 was a kind gift from CVGI Research Area,
AstraZeneca (Alderley Park, UK). Corning® CellBIND® microplates
were from Corning B.V. Life Sciences (Schipol-Rijk, The Netherlands),
96-well UNIFILTER®microplate fromWhatman (Middlesex, UK), and
96-well Wallac Isoplates, TopSeal for 96-well microplates and the
scintillation liquid Optiphase Supermix was from PerkinElmer
(Waltham, MA, USA). The ATPlite 1 step kit was from PerkinElmer
Life and Analytical Sciences (Shelton, CT, USA). Bio-Rad Protein Assay
Dye Reagent was from Bio-Rad Laboratories (NY, USA). Thin layer
chromatography (TLC) plates (Silica gel) were from Merck (Darm-
stadt, Germany). The primers for CD36, FAS, SCD-1, ACC, ChREBP,
PDK-4, CYC1, CPT-1A, CPT-1B, UCP-2 and UCP-3 and the housekeeping
genes GAPDH and 36B4 were provided by Invitrogen (Carlsbad, CA,
USA). SYBR green and TaqMan reverse transcription kit reagents were
obtained from Applied Biosystems (Warrington, UK). Agilent Total
RNA isolation kit was purchased from Agilent Technologies (Santa
Clara, CA, USA). Primers and probes for ND1 and B2M and qPCR
MasterMix Plus Low ROX were from Eurogentec (Seraing, Belgium).
Puregene DNA isolation kit was from Gentra Systems, Qiagen
(Germantown, MD, USA).
2.2. Human skeletal muscle cell cultures
Satellite cells were isolated from the Musculus obliquus internus
abdominis of 8 healthy donors, age 39.9 (±2.9) years, body mass
index 23.5 (±1.4) kg/m2, fasting glucose 5.3 (±0.2) mmol/l, insulin,
plasma lipids and blood pressure within normal range and no family
history of diabetes. The biopsieswere obtainedwith informed consent
and approval by the National Committee for Research Ethics, Oslo,
Norway. The cells were cultured in DMEM-Glutamax (5.5 mmol/
l glucose) with 2% FCS, 2% Ultroser G, penicillin/streptomycin (P/S)
and amphotericin B until 70–80% conﬂuence. Myoblast differentiation
to myotubes was then induced by changing medium to DMEM-
Glutamax (5.5 mmol/l glucose) with 2% FCS, 34 pmol/l insulin, P/S and
amphotericin B. Experiments were performed after 8 days of
differentiation, and pre-incubation with hyperglycemia (20 mmol/
l glucose) was started after 4 days.
2.3. Substrate oxidation assay
The muscle cells were cultured on 96-well CellBIND® microplates
as described above. Growth medium was completely removed before
addition of substrates. Substrate, [1-14C]glucose (37 kBq/ml), [6-14C]
glucose (37 kBq/ml), [14C(U)]glucose (37 kBq/ml) or [1-14C]oleic acid
(37 kBq/ml), was given in DPBS with 10 mmol/l HEPES and 1 mmol/
l L-carnitine (only added with oleic acid). Oleic acid was bound to BSA
at a ratio of 2.5/1. A 96-well UNIFILTER® microplate was mounted on
top of the CellBIND® plate as described before [26], and the cells were
incubated at 37 °C for 4 h. The CO2 trapped in the ﬁlter was counted by
liquid scintillation in a MicroBeta™ Trilux scintillation counter
(PerkinElmer). The remaining cell-associated radioactivity was also
assessed by liquid scintillation, and the sum of CO2 and cell-associated
radioactivity was considered as total substrate uptake. Oxidation of
[1-14C]oleic acid to acid-soluble metabolites (ASM) was measured by
acidic precipitation of the incubation media. CO2 production from [1-
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compounds known to modify mitochondrial function; dinitrophenol
(DNP 100 μmol/l) and carbonylcyanide-4-triﬂuoromethoxyphenylhy-
drazone (FCCP 0.6 mmol/l) (both mitochondrial uncouplers), and
oligomycin (ATP synthase inhibitor, 1 μg/ml). From these experi-
ments we calculated baseline (routine) oxidation (R) and uncoupled
oxidation with FCCP (E), as well as baseline oxidation in the presence
of oligomycin (L) [27]. The net routine ﬂux control ratio was
calculated as netR=(R−L)/E. Protein content in each well was
determined [28], and the data are presented as CO2/mg protein, cell-
associated substrate/mg protein or ASM/mg protein.
2.4. Lipid distribution
Myotubes were incubated with [1-14C]oleic acid (18.5 kBq/ml,
0.2 mmol/l) for 4 h before they were harvested into ice-cold water,
centrifuged (1000g, 5 min), resuspended in distilledwater and sonicated.
Cell-associated lipids were extracted with chloroform:methanol and
separated by thin layer chromatography as described by Folch et al. [29].
2.5. RNA isolation and analysis of gene expression by real-time RT-PCR
Human skeletal muscle cells were washed, trypsinized and
pelleted before total RNA was isolated using Agilent Total RNA
isolation kit (Agilent Technologies, Santa Clara, CA, USA) according to
the supplier's protocol. Total RNA (0.1 μg/μl) was reversely tran-
scribed with oligo primers using a PerkinElmer Thermal Cycler 9600
(25 °C for 10 min, 37 °C for 1 h, 99 °C for 5 min) and a TaqMan
reverse-transcription reagents kit (Applied Biosystems, Warrington,
UK). Real-time PCR was performed using an ABI PRISM® 7000
Detection System (Applied Biosystems, Warrington, UK). DNA
expression was determined by SYBR® Green, and primers were
designed using Primer Express® (Applied Biosystems, Warrington,
UK) (sequences in Table 1). Each target were quantiﬁed in triplicatesTable 1
Primer sequences.
Gene Acc. no. Primer
GAPDH NM_002046 Forward: TGCACCACCAACTGCTTAGC
Reverse: GGCATGGACTGTGGTCATGAG
36B4 M17885 Forward: CCATTCTATCATCAACGGGTACAA
Reverse: AGCAAGTGGGAAGGTGTAATCC
CD36 L06850 Forward: AGTCACTGCGACATGATTAATGGT
Reverse: CTGCAATACCTGGCTTTTCTCAA
FAS U26644 Forward: GAACTCCTTGGCGGAAGAGA
Reverse: GTTCTGAGAAAGGTCGAATTTGC
SCD-1 AB032261 Forward: CTCCCCTGCCACACTGATG
Reverse: GAGCGCTTGGCTTCTCATG
ACC1 U10822 Forward: AGAATTCACCCAGCAAAATAAAGCTA
Reverse: CTCCGATCCACCTCATAGTTGAC
ChREBP NM_032951 Forward: CGGCATTGAGCTCCTCAATC
Reverse: GCAGAAGACAGCTGAGTACATCCTTA
CYC1 NM_001916 Forward: CTGCCAACAACGGAGCATT
Reverse: CGTGAGCAGGGAGAAGACGTA
CPT-1B NM_004377 Forward: GAGGCCTCAATGACCAGAATGT
Reverse: GTGGACTCGCTGGTACAGGAA
CPT-1A NM_001876 Forward: TGCTTTACAGGCGCAAACTG
Reverse: TGGAATCGTGGATCCCAAA
PDK-4 BC040239 Forward: TTTCCAGACCAACCAATTCACA
Reverse: TGCCCGCATTGCATTCTTA
UCP-2 AF019409.1 Forward: CCTGCGGCTCGGACACATA
Reverse: GGGGCACCTTTAATCAGCAACA
UCP-3 AF050113 Forward: AGGACCTTTGCCCAACATCATG
Reverse: AGTCCAGCAGCTTCTCCTTGAG
ND1 Forward: CCCTAAAACCCGCCACATCT
Reverse: GAGCGATGGTGAGAGCTAAGGT
B2M Forward: TGCTGTCTCCATGTTTGATGTATCT
Reverse: TCTCTGCTCCCCACCTCTAAGT
ND1 probe: FAM-CCATCACCCTCTACATCACCGCC-BHQ.
B2M probe: HEX-TTGCTCCACAGGTAGCTCTAGGAGG-BHQ.and carried out in a 25 μl reaction volume according to the supplier's
protocol. All assays were run for 40 cycles (95 °C for 12 s followed by
60 °C for 60 s). The transcription levels were normalized to the
reference genes GAPDH and 36B4.
2.6. Microarray
Total RNA was prepared from primary myotubes from three
donors using Agilent Total RNA isolation kit according to the supplier's
protocol (Agilent Technologies). RNA was used individually and RNA
integrity was checked on chip analysis (Agilent 2100 bioanalyzer,
Agilent Technologies, Santa Clara, CA, USA) according to the
manufacturer's instructions. RNA was judged as suitable for array
hybridization only if samples exhibited intact bands corresponding to
the 18S and 28S ribosomal RNA subunits, and displayed no
chromosomal peaks or RNA degradation products (RNA Integrity
NumberN9.0). cRNA synthesis was performed using Illumina Total-
Prep RNA Ampliﬁcation (San Diego, CA, USA) according to the
supplier's protocol. Hybridization, washing, and scanning of Illumina
Human-6 Express BeadChips version 3 arrays (N 48000 probes) were
according to standard Illumina protocols (San Diego, CA, USA). Data
extraction and quality control was performed using BeadStudio
version 3.1.3.0 (Illumina) and the Gene Expression module 3.2.7.
Arrays were normalized using quantile normalization, and expression
estimates were calculated by GC robust multiarray average back-
ground adjustment. Fold change (FC) was calculated as log2-
transformed expression level after HG treatment divided by log2-
transformed expression level after NG treatment (control), followed
by identiﬁcation of differentially expressed probe sets using Intensity-
based moderated t-statistics [30]. p-Values were corrected for
multiple testing by using Benjamini and Hochberg's false discovery
rate (FDR) method [31]. Probe sets that satisﬁed the criterion of
FDRb10% (q-valueb0.1) and fold-change N1.2 or b−1.2, were
considered to be signiﬁcantly regulated. GEO accession number
GSE19620.
2.7. Mitochondrial DNA copy measurement
DNA was isolated from whole cell lysates by PureGene DNA
isolation kit (Qiagene, Germantown, MD, USA). Quantiﬁcation of
mitochondrial DNA (mtDNA) relative to nuclear DNA (nDNA) was
done by real-time qPCR with TaqMan probes using a Stratagene
3000mxp. Primer and probe sequences were taken from He et al [32],
Bogacka et al. [33] and Bai et al. [34], and conﬁrmed with Primer3.
Each target were quantiﬁed in triplicates and carried out in a 25 μl
reaction volume (12.5 μl 2×qPCR mix (dNTP, HotGoldStar DNA
polymerase, MgCl2 (5 mmol/l), ROX), 0.75 μl fwd primer (300 nmol/
l), 0.75 μl rew primer (300 nmol/l), 0.5 μl probe (200 nmol/l), 5 μl
template (10 ng), 5.5 μl H2O). All assays were run for 95 °C in 10 min
followed by 45 cycles of 95 °C for 15 s and 60 °C for 60 s. The threshold
cycle number (Ct) was used for calculating the relative copy number
(Rc) by expressing differences in Ct of the mtDNA and nDNA qPCR:
Rc=2ΔCt [35,36].
2.8. Immunoblotting
Aliquots with 20 μg cell protein (total cell lysate prepared in
Laemmli buffer) were separated by SDS-PAGE (10% resolving gel) and
transferred to polyvinylidene diﬂuoride membranes. The membranes
were immunoblotted with AMPK (1:1000), phospho-AMPK (1:1000),
ACC (1:1000) and phospho-ACC (1:1000) antibodies (Cell Signaling
Technology, Beverly, MA, US) over night. Immunoreactive bands were
visualized with enhanced chemiluminescence (ECL) (Amersham
Biosciences, Buckinghamshire, UK), and quantiﬁed with Gel-Pro
Analyzer (version 2.0) software.
Fig. 1. Suppression of oleic acid oxidation by acute glucose. Myotubes were incubated
with [1-14C]oleic acid (OA) (37 kBq/ml, 100 μmol/l) for 4 h in presence of 0, 0.1, 0.5, 1, 2
or 5 mmol/l glucose. CO2 was trapped in a ﬁlter and counted by liquid scintillation as
described in Experimental. Complete oleic acid oxidation to CO2 is given asmean±SEM
(n=5).
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Intracellular concentration of ATP in NG and HG cells was
measured with ATPlite 1step kit from PerkinElmer Life and Analytical
Sciences (Shelton, CT, USA). Luminescence was detected with Victor3
Wallac 1420 multilabel counter (PerkinElmer). ATP concentration
was quantiﬁed according to a standard curve and given as μMATP/mg
cell protein. DNP (100 μmol/l) which was added as a control, reduced
ATP concentration by 30%.
Cell medium lactate concentration was measured with a radiom-
eter ABL 715 blood gas analyzer (Diamond Diagnostics, Holliston, MA,
USA). Medium from 6 well plates were harvested after 48 h and
analyzed without dilution.
2.10. Protein synthesis
The cells were grown in CytoStar-T scintillating microplates and
incubatedwith [14C(U)]leucine (37 kBq/ml, 0.8 mmol/l) on day 8 after
initiated differentiation. Incorporation of [14C]leucine was followed
for 10 h with scintillation proximity assay (SPA) technology. Uptake
and accumulation of leucine in cells treated with hyperglycemia
(20 mmol/l glucose for 4 days) were compared to normoglycemic
control cells (5.5 mmol/l glucose).
2.11. Statistics
All data are presented as mean±SEM. Statistical comparison
between different treatments was performed by Student's t-test and
linear mixed models (LMM) analysis (SPSS ver. 16.0). The parameter
of interest was entered as the dependent variable and pretreatment
(HG and NG) and acute treatments were entered as ﬁxed variables.
Differences were considered statistically signiﬁcant at pb0.05. All
experiments were performedwith at least triplicate observations, and
replicate experiments are performed on cells from different donors
and given as n.
3. Results
3.1. Effect of acute glucose on oleic acid oxidation
Simultaneous accumulation and oxidation of oleic acid (OA) was
determined in human skeletal muscle cells (myotubes) as previously
described [26]. The suppressive effect of acute addition (4 h during
CO2 trapping) of glucose on [1-14C]OA oxidation was evident at
0.5 mmol/l glucose (Fig. 1), and at 5 mmol/l glucose OA oxidation was
suppressed by 53%. OA oxidation was not signiﬁcantly suppressed by
acute addition of 5 mmol/l deoxyglucose (DOG), 1.43 (±0.83) nmol/
mg protein of CO2 was trapped in absence and 1.07 (±0.55) nmol/mg
protein in presence of 5 mmol/l DOG (p=0.31, n=3), indicating that
the suppressive effect of glucose on OA oxidation is due to some
downstream metabolites in the glycolytic pathway.
3.2. Effect of chronic hyperglycemia on oleic acid metabolism
To examine whether chronic hyperglycemia affects the suppres-
sive effect of glucose on OA metabolism, myotubes were pretreated
with hyperglycemia (HG, 20 mmol/l glucose) for 4 days and OA (0–
300 μmol/l) metabolismwasmeasured in the absence and presence of
acute glucose (5 mmol/l) (Fig. 2). As shown in Fig. 1, acute glucose
(5 mmol/l) suppressed OA-oxidation to CO2 by 50% in normoglycemic
cells (Fig. 2A, pb0.0005 overall effect), whereas this suppressive effect
of acute glucose was not signiﬁcant in hyperglycemic cells (Fig. 2B).
Chronic exposure to HG reduced complete oxidation of OA to CO2 by
47% compared to exposure to NG (Fig. 2A and B, pb0.0005, overall
effect), indicating that oxidation was already suppressed after chronic
HG exposure. Incomplete OA oxidation to acid-soluble metabolites(ASM) was however increased by 22 (±8)% in HG cells compared to
NG cells (p=0.02, data not shown). ASM consist mainly of
tricarboxylic acid cycle metabolites and reﬂect incomplete oxidation
of fatty acids. Acute glucose did not suppress ASM production, neither
in NG nor HG cells (data not shown).
Cellular uptake of OA in NG cells, assessed as the sum of cell-
associated and CO2-trapped radioactivity, increased with increasing
concentrations of OA (20–300 μmol/l) (pb0.0005) and in presence of
glucose (pb0.0005) (Fig. 2C). HG cells on the other hand showed no
signiﬁcantly increased OA uptake with increasing OA concentrations
(p=0.12) or in presence of glucose (p=0.56) (Fig. 2D), showing a
reduced sensitivity towards acute glucose after chronic HG exposure.
The overall cellular uptake of OAwas also signiﬁcantly reduced by 32%
in HG cells (p=0.004). However, myotubes exposed to HG showed
21% increased incorporation of OA into triacylglycerol compared to
NG cells (p=0.02, data not shown), in accordance with previous
ﬁndings [24]. The other lipid classes (free fatty acid, diacylglycerol,
phospholipids, and cholesterol ester) were not signiﬁcantly affected
by HG pretreatment.
The fraction of OA that was oxidized (CO2/cellular uptake) was
independent of OA concentration, 4.7 (±0.5)% in NG cells and 4.4
(±0.5)% in HG cells in absence of glucose. Glucose reduced this
fraction signiﬁcantly in NG cells to 1.5 (±0.2)% (pb0.0005), whereas
there was no signiﬁcant reduction (2.6 (±1.0)% (p=0.17)) in HG
cells. The observed effects of HG on metabolism, was not due to
hypertonicity as previously shown [24].3.3. Glucose suppressibility and adaptability in myotubes treated with
chronic hyperglycemia
To investigate whether HG affected metabolic switching, the
parameters suppressibility and adaptability were calculated according
to previous deﬁnitions [5]. Glucose suppressibility, the ability of
acutely added glucose to suppress lipid oxidation, was markedly
reduced to 21% in HG cells compared to 50% in NG cells (Fig. 3A)
(p=0.03). Adaptability, deﬁned as the capacity to increase lipid
oxidation upon exposure to increasing fatty acid concentrations, was
present in both NG and HG cells (p=0.04 overall effect). The
adaptability seemed to be reduced in cells pretreated with HG,
although not signiﬁcantly (Fig. 3B).
Fig. 2. Oleic acid metabolism in normoglycemic (NG) and hyperglycemic (HG) cells in absence and presence of acute glucose (5 mmol/l). Myotubes were pretreated with 5.5 mmol/
l glucose (NG) or 20 mmol/l glucose (HG) for 4 days before they were incubated with [1-14C]oleic acid (OA) (37 kBq/ml, 20–300 μmol/l) for 4 h in absence or presence of acute
glucose (5 mmol/l). CO2 (A, B) was trapped in a ﬁlter and counted by liquid scintillation as described in Fig. 1. Uptake of OAwas assessed as the sum of oxidized OA (trapped CO2) and
remaining cell-associated radioactivity (C, D). Data are given as mean±SEM (n=3–5).
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hyperglycemic cells
The effect of hyperglycemia on glucose metabolism was also
examined. Glucose uptake, assessed as the sum of cell-associated
and CO2-trapped radioactivity from [6-14C]glucose, was reduced by
exposure to hyperglycemia for 4 days (Fig. 4A), as reported before
using a standard deoxyglucose uptake assay [24]. The overall
glucose uptake in HG cells was 61% of the amount measured in NG
cells (p=0.03).
To evaluate the effect of fatty acids on glucose metabolism, oleic
acid (OA) was added to the cell culture media during acute glucose
uptake (4 h) in concentrations up to 300 μmol/l. Glucose uptake
seemed to increase with increasing OA concentrations, although not
signiﬁcantly (p=0.06), and there was no difference between NG and
HG cells (Fig. 4A).
Oxidation of glucose to CO2was reducedbyHG to the samedegree as
glucose uptake, to 62% of control cells (p=0.03, Fig. 4B). There was nosigniﬁcant effect of acute oleic acid addition on glucose oxidation. The
fraction of glucose thatwas oxidized (CO2/cellular uptake)was constant
and not dependent on chronic hyperglycemia or concentration of oleic
acid (data not shown). The effect of hyperglycemia on glucose
metabolism was conﬁrmed with two other isotopes of glucose, [1-14C]
glucose (data not shown) and [14C(U)]glucose (Fig. 5B).
3.5. Effect of chronic hyperglycemia on mitochondrial capacity
To determine the mitochondrial capacity of myotubes pretreated
with NG or HG, complete oleic acid oxidation and glucose oxidation to
CO2 was measured in presence of the mitochondrial uncoupler 2.4-
dinitrophenol (DNP). DNP (100 μmol/l) increased OA oxidation 1.5-
fold in both NG and HG cells in absence of glucose (Fig. 5A). In
accordance with the results in Fig. 2, glucose suppressed OA oxidation
by about 50% in NG cells, and 20% in HG cells. There was no
statistically signiﬁcant difference between NG and HG in maximal
fatty acid oxidation in presence of DNP. With DNP, acute glucose
Fig. 3. Suppressibility (A) and adaptability (B) of oleic acid (OA) oxidation in NG and HG cells. Suppressibility was calculated as [1-(OA oxidation (100 μmol/l) in presence of 5 mmol/
l glucose/OA oxidation at 0 mmol/l glucose)]×100%. Adaptability was calculated as fold increase in OA oxidation from 20 μmol/l OA, here 0 mmol/l and 5 mmol/l glucose aremerged.
These data were calculated from the results in Fig. 2. ⁎pb0.05 vs. NG.
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Additional experiments on OA oxidation were performed to further
investigate mitochondrial energy production. By use of compounds
modifying substrate oxidation and calculating net routine ﬂux control
ratio (netR) (see Experimental) we observed that 52% of electron
transport system (ETS) capacity was activated for ATP production in
NG cells, whereas this was decreased to 41% after HG treatment
(p=0.04, n=3).
The maximal capacity to oxidize [14C(U)]glucose was strongly
compromised in HG cells (Fig. 5B) to only 47% of the capacity seen in
NG cells (pb0.001). In presence of DNP, the suppressive effect of OA
on glucose oxidation (OA suppressibility) was also evident. OAFig. 4. Glucose metabolism at increasing oleic acid concentrations in normoglycemic (NG) an
20 mmol/l glucose (HG) for 4 days before incubation with [6-14C]glucose (37 kBq/ml, 5 mm
assessed as the sum of cell-associated glucose and trapped CO2 (A) and CO2 production from
(n=3).suppressibility was signiﬁcantly lower in HG compared to NG cells
(23% vs. 42% in HG and NG cells, respectively, Fig. 5C).
3.6. Gene regulation by chronic hyperglycemia
To further elucidate the molecular mechanism behind the effects
of hyperglycemia on glucose and lipid metabolism, we examined by
real-time RT-PCR and microarray analysis, gene expression in NG and
HG cells. Some of the essential genes involved in carbohydrate
(ChREBP, PDK-4) and fatty acid metabolism (FAS, SCD-1, ACC) and
fatty acid uptake (CD36) were examined by real-time RT-PCR (Fig. 6).
HG did not affect the gene expression level of any of the examinedd hyperglycemic (HG) cells. Myotubes were pretreated with 5.5 mmol/l glucose (NG) or
ol/l) for 4 h in presence of 0–300 μmol/l oleic acid during CO2 trapping. Glucose uptake
glucose (B) were assessed as described in Experimental. Data are given as mean±SEM
Fig. 5.Oxidation of oleic acid and glucose in presence of themitochondrial uncoupler 2.4-dinitrophenol (DNP). Myotubes were pretreated with 5.5 mmol/l glucose (NG) or 20 mmol/
l glucose (HG) for 4 days before they were incubated with radiolabeled substrates in the absence or presence of DNP (100 μmol/l) for 4 h. (A) [1-14C]oleic acid (OA) (37 kBq/ml,
100 μmol/l) in absence or presence of acute glucose (5 mmol/l) and (B) [14C(U)]glucose (37 kBq/ml) in absence or presence of acute OA (100 μmol/l). (C) Oleic acid suppressibility of
glucose oxidation was calculated as [1-(glucose oxidation in presence of 100 μmol/l OA/glucose oxidation without OA added] *100%. Data are given as mean (±SEM) (n=4).
*pb0.05 vs. basal oxidation without acute glucose and without DNP, §pb0.05 vs. basal oxidation without acute OA and without DNP, ¤pb0.05 vs. NG, #pb0.05 vs. NG+DNP.
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(CPT1, CYC1, UCP-2 and UCP-3) changed (Fig. 6). The gene 36B4 was
used as reference gene, and similar results were obtained when gene
expression were related to the reference gene glyceraldehyd-3-
phosphate dehydrogenase (GAPDH) (data not shown). Microarray
analysis of gene expression surprisingly showed that no genes were
signiﬁcantly regulated by 4 days of chronic HG (data not shown,
Illumina arrays with N48000 probes, GSE19620). However, it must be
emphasized that cells from only 3 subjects were included in these
experiments, and that might be too few to detect small changes.3.7. Mitochondrial DNA, ATP and lactate concentration
Since mitochondrial capacity seemed to be reduced after chronic
HG compared to NG, we wanted to examine the mitochondrialFig. 6. Gene expression in myotubes after pretreatment with hyperglycemia (HG) for
4 days relative to normoglycemic (NG) cells. Data are given as mean±SEM (n=4).
Expression of the fatty acid transporter CD36, fatty acid synthase (FAS), stearoyl-CoA
desaturase (SCD-1), acetyl CoA carboxylase (ACC), carbohydrate responsive element
binding protein (ChREBP), cytochrome c (CYC1), carnitine palmitoyltransferase (CPT-
1A, -1B), pyruvate dehydrogenase kinase (PDK-4) and uncoupling proteins (UCP-2, -3)
were studied relative to the reference gene 36B4 by real-time PCR as described in
Experimental.content, by measuring mitochondrial DNA, of the myotubes. Mito-
chondrial DNA relative to nuclear DNA was not altered by HG
(Fig. 7A). However, cells exposed to HG contained 25% less ATP than
NG cells (Fig. 7B, p=0.03).
To examine whether the HG effect could be explained by an
increased production of lactate, myotubes were pretreated with
sodium lactate (1 or 10 mmol/l) for 1–4 days before glucose
oxidation was measured (Fig. 8A). The effect of HG on glucose
oxidation was mimicked by lactate, at 10 mmol/l lactate for 4 days
glucose oxidation was reduced by 44% (p=0.03). The effect of lactate
on glucose uptake was similar to the effects on oxidation (Fig. 8B).
Preincubation with sodium lactate (10 mmol/l) also reduced OA
oxidation to the same extent as HG (data not shown). Addition of
sodium lactate to the cell media did not change pH. For comparison
the effect of lactic acid (0.01, 0.1 or 0.2 mmol/l) was examined on
glucose oxidation and uptake, and a similar effect as of HG and lactate
treatments was observed (Fig. 8C and D). In this case, pH of the
culture medium was reduced to 6.8. The calculated concentration of
non-dissociated lactic acid in the media was similar after addition of
lactate and lactic acid. To exclude an effect of acidiﬁcation, HCl was
added in an amount that gave the same reduction in pH as lactic acid,
but HCl had no effect on glucose oxidation (data not shown). Insulin-
stimulated glucose uptake was abolished by HG (Fig. 9). Lactate
seemed to reduce the insulin responses as well, although not
signiﬁcantly (p=0.14). However, the lactate concentration in the
cell media was only slightly increased in cells exposed to HG for
4 days, 4.0 (±0.6) mmol/l versus 3.7 (±0.5) mmol/l in media from
NG cells (n=5, p=0.08). The average pH value in the cell media was
similar, 7.2 (±0.2) in both HG and NG. This implied a speciﬁc effect of
lactate independent of pH.
Impaired glucose oxidation, reduced ATP concentrations and
increased lactate production could be explained by a dysfunctional
pyruvate dehydrogenase (PDH) complex. To test whether HG
impaired PDH activity, glucose oxidation was measured after
incubation with a new PDHK inhibitor, AZD7545 (10–100 nM for 2–
4 days). The HG-induced reduction of glucose oxidation was not
abolished by the PDHK inhibitor. Glucose oxidation was reduced by
22% after chronic HG to 13.8 (±0.9) nmol CO2/mg protein in cells
without PDKH inhibition and by 23% to 10.6 (±1.8) nmol CO2/mg
protein in myotubes pretreated for 4 days with a combination of HG
and 100 nM AZD7545 (n=3). The activity of the inhibitor was
conﬁrmed by an acute stimulatory effect on glucose oxidation.
Fig. 7. Mitochondrial DNA (A) and ATP concentration (B) in human myotubes. The myotubes were grown in normoglycemic medium (NG) or in medium containing 20 mmol/
l glucose (HG) for 4 days before mitochondrial DNA (mtDNA) relative to nuclear DNA (nDNA) was measured by real-time PCR, and ATP concentration was measured with an ATPlite
1step kit as described in Experimental. Data are given as mean (±SEM) (n=5–7). *pb0.05 vs. NG.
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cells and by 35% in HG cells.
3.8. Activation of AMPK
AMPK is known to be an important energy sensor in cells. The
involvement of AMPK in HG-treated myotubes was therefore of
interest. HG had no effect on either AMPK or ACC phosphorylation
compared to NG control cells (data not shown). However, pretreat-
ment with deoxyglucose (DOG) increased phosphorylation of both
AMPK and ACC to the same extent in NG and HG cells, showing
responses to acute energy depletion.
3.9. Effect of chronic hyperglycemia on protein synthesis
To explore the effect of HG on cellular viability and energy
requirement, protein synthesis was assessed as [14C(U)]leucine
uptake and accumulation, measured by a scintillation proximity
assay (SPA). Protein synthesis was about 2-fold increased after
chronic HG (p=0.02 overall effect), indicating that hyperglycemia
did not cause a reduced energy requirement (Fig. 10). Leucine uptake
and accumulation was stimulated by insulin (100 nmol/l) in both NG
and HG cells. After 10 h insulin-stimulated [14C(U)]leucine accumu-
lation was increased by 35.6 (±7.4) nmol/mg protein in NG cells and
by 24.7 (±10.2) nmol/mg protein in HG cells, showing an impaired
relative insulin response on protein synthesis in HG-treated cells
(p=0.04, data not shown).
4. Discussion
In the present study we showed that chronic exposure of
differentiated human skeletal muscle cells (myotubes) to hypergly-
cemia (HG) signiﬁcantly reduced both glucose and oleic acid
oxidation and reduced the suppressive effect of acute glucose on
oleic acid oxidation. Glucose oxidation in presence of a mitochondrial
uncoupler (DNP) was also markedly reduced, and the same was
cellular ATP concentration. Mitochondrial content, as measured by
mitochondrial DNA, was unchanged and so was the expression level
of several mitochondrial genes. Moreover, HG did not affect the
expression level of any genes measured by real-time RT-PCR ormicroarray. Addition of lactate to control cells mimicked the effect of
HG on inducing insulin resistance and reducing substrate oxidation. In
addition, lactate concentration in cell media was slightly increased
after hyperglycemia. These results imply that chronic hyperglycemia
can induce impaired metabolic switching and reduce substrate
oxidation in healthy myotubes without changing gene expression.
Metabolic switching of myotubes, characterized by the parameters
suppressibility and adaptability, has been suggested to be of intrinsic
origin and to correlate with in vivo characteristics [4]. However,
metabolic switching can also be affected by extrinsic factors, as we
recently showed that n-3 fatty acids improve metabolic switching of
myotubes [5]. In the present study, glucose suppressibility (the
suppressive effect of acute glucose on oleic acid oxidation) was
signiﬁcantly reduced by chronic HG. Adaptability (the capacity to
increase fatty acid oxidation with increasing fatty acid availability)
seemed to be reduced by HG exposure, although not signiﬁcantly. This
induced impairment of metabolic switching was not observed in the
opposite situation; oleic acid suppressibility of glucose oxidation at
baseline conditions. However, in presence of DNP, at maximal
mitochondrial electron transport system (ETS) capacity, a suppressive
effect of oleic acid on glucose oxidation was evident after both NG and
chronic HG pretreatment of the cells, although signiﬁcantly lower
after HG. A possible explanation could be that glycolytic metabolism is
preferred in these cells, and that a substrate competition was evident
only at maximum ﬂux through the ETS caused by DNP.
The acute glucose suppression of lipid oxidation has similarities
with the switch from fatty acid to carbohydrate oxidation in the
postprandial phase and at high intensity exercise. The mechanism
behind this substrate switch is not known, but the suppressive effect
on CO2 but not on ASM indicates an effect downstream of fatty acid β-
oxidation. The mechanism is probably due to a mitochondrial
competition between carbohydrates and fatty acids. This could be
mediated by malonyl-CoA inhibiting CPT1 and thereby entry and
oxidation of fatty acids in mitochondria [37,38]. Another explanation
focus on the ETS, and is based on that catabolism of carbohydrates
produces redox equivalents (NADH) feeding electrons into complex I,
whereas catabolism of fatty acids produces redox equivalents feeding
electrons into both complex I and II. Substrate competition at ETS level
could possibly be explained by differences in relative activity of the
complexes and in feedback control on PDH and β-oxidation by redox
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Fig. 8. Effect of sodium lactate and lactic acid on glucose oxidation and uptake. Myotubes were preincubated with sodium lactate (1 and 10 mmol/l) (A, B) or lactic acid (10–
200 μmol/l) (C, D) for 4 days, before CO2 production from [14C(U)]glucose (37 kBq/ml, 5 mmol/l) was measured for 4 h. Glucose uptake was assessed as the sum of cell-associated
glucose and trapped CO2. Data are given as mean (±SEM) (n=4). *pb0.05 vs. NG.
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showed that maximal oxidation capacity of glucose, but not OA, was
compromised by HG, suggesting a defect at the complex I level or
upstream. Measurements of mitochondrial function using OA as
substrate further revealed that 21% less of ETS capacity was activated
for ATP production after HG treatment.
The present results indicate that chronic exposure of myotubes to
high glucose concentration impairs mitochondrial function. Complete
oxidation of glucose and oleic acid to carbondioxide was reduced.
Incomplete oxidation of oleic acid, i.e. production of acid-soluble
metabolites (ASM), was increased, as was oleic acid distribution intointracellular triacylglycerol (TAG), in accordance with previous
ﬁndings [24]. The increased storage of oleic acid as TAG could partly
explain why HG suppresses oleic acid oxidation. Decreased complete
oxidation in combinationwith increased incomplete oxidation of fatty
acids as observed after chronic HG exposure has also been reported to
occur in myotubes from obese type 2 diabetic individuals [40].
Moreover, an imbalance between β-oxidation and TCA cycle or
electron transport chain activity has been suggested to lead to
increased incomplete fatty acid oxidation and accumulation of lipid-
derived metabolites in the mitochondria, further resulting in
mitochondrial stress and development of skeletal muscle insulin
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Fig. 9. Insulin-stimulated glucose uptake in myotubes. Myotubes were preincubated
with normoglycemia (5.5 mmol/l glucose, NG), hyperglycemia (20 mmol/l glucose,
HG), sodium lactate (10 mmol/l) or lactic acid (0.01 mmol/l) for 4 days, before insulin-
stimulated (100 nmol/l) glucose uptake was measured. CO2 production from [14C(U)]
glucose (37 kBq/ml, 5 mmol/l) was measured for 4 h, and glucose uptake was assessed
as the sum of cell-associated glucose and trapped CO2. Insulin-stimulated glucose
uptake is given as % of basal (glucose uptake in absence of insulin). Data are given as
mean (±SEM) (n=4). *pb0.05 vs. NG.
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might be due to an affected step somewhere in the TCA cycle or
electron transport chain machinery, leading to accumulation of lipid-
derived metabolites in the mitochondria and possibly impaired
metabolic switching.
Glycolytic products such as lactate and pyruvate might play a
regulatory role in the mechanism behind metabolic switching. The
effect of HG on glucose uptake and oxidation was mimicked by
extracellular addition of lactate. The activity of CPT-1 is strongly pH-Fig. 10. Protein synthesis in normoglycemic (NG) and hyperglycemic (HG) myotubes.
The cells were grown in CytoStar-T scintillating microplates and incubated with
[14C(U)]leucine (37 kBq/ml, 0.8 mmol/l) as described in Experimental. Incorporation of
[14C]leucine was followed for 10 h with scintillation proximity assay (SPA) technology.
Data are given as mean±SEM (n=3).dependent, and could possibly be inhibited by lactate [44]. However,
in the present study addition of lactate also inhibited glucose
oxidation and this effect was rather speciﬁc since acidiﬁcation by
HCl did not decrease glucose oxidation. In addition, lactate did not
change the pH of the cell culture medium. A speciﬁc effect of lactate is
also supported by the lactic acid experiments. Recently, lactate was
found to be the ligand for the orphan G-protein-coupled receptor
GPR81, and it was shown that lactate regulated adipocyte lipolysis
through this receptor [45]. In muscle lactate is known to decrease
glucose consumption and glycolytic ﬂux [46]. Although lactate
concentration was only slightly increased in cell media of myotubes
exposed to chronic HG, it suggests that glucose oversupply pushes the
glycolytic pathway. Intramyocellular lactate concentration was not
measured, but could be increased to a greater extent. Possibly,
recycling of lactate back into glucose could also explain the reduced
ATP level, and there exist evidence that this futile cycle is active in
myotubes [47]. An increased lactate production can be caused by
increased lactate dehydrogenase activity, reduced activity of pyruvate
dehydrogenase (PDH) or lack of acetyl CoA. PDH activity is controlled
by PDH kinase, and if HG increased PDHK activity and thereby reduced
PDH activity, an inhibitor of PDHK might then relieve the HG effect.
The PDHK inhibitor, AZD7545, however showed no effect on the
reduced glucose oxidation caused by HG. Changed PDH activity by any
other mechanism can however not be excluded by these experiments.
Whether the effect of HG is mediated by lactate is uncertain, and
should bemore thoroughly studied. Any effect of lactate or chronic HG
on lipolysis in muscle is not known and should also be examined. The
present ﬁnding of increased storage of oleic acid as triacylglycerol
(TAG), together with previous observations of increased TAG content
in myotubes treated with chronic hyperglycemia [24] could imply
that lipolysis might be affected. In theory, glucose oversupply could
also possibly increase cell glycogen content and thereby favor
utilization of glucose derived from stored glycogen and suppress
lipid oxidation. However, based on previous results we have no
reasons to believe that glycogen content is increased after HG in
absence of insulin [24].
The reduced mitochondrial capacity could not be explained by
altered gene expression or by a decreased number of mitochondria. In
fact, the protein synthesis experiments showed that the cells in
energy surplus were more actively accumulating leucine, indicating
high metabolic activity. This is in accordance with a previous study
showing increased protein synthesis in hyperglycemic diabetic
patients [48]. Resistance towards insulin-stimulated protein anabo-
lism has also been reported in type 2 diabetics [49]. Insulin-stimulated
protein synthesis was reduced in cells pretreated with HG conﬁrming
insulin resistance, which was also observed on glucose uptake. Why
the muscle cells then turn down energy production (ATP) and
increases energy storage is not known. Of course, other energy
demanding processes than protein synthesis could be affected by HG,
such as calcium recycling or other membrane-associated pumping
activities.
Surprisingly, no genes were found to be signiﬁcantly regulated by
chronic HG. These results suggest that the metabolic effects of HG
might be mediated by altered protein activities caused by some form
of post-translational modiﬁcation, e.g. phosphorylations, glycations or
acetylations. Previously, we have reported that neither phosphoryla-
tion of PKB [24] nor ERK [50] is affected by chronic HG. Glucose
infusion to rats has been shown to induce increased PKC activation
[51] and to reduce phosphorylation and activation of AMPK, an
important sensor of energy status and regulator of energymetabolism
in cells [52]. In the present study, chronic HG did not change
phosphorylation of AMPK or its substrate ACC. These data suggest that
although energy uptake and oxidation is reduced, the cells are in an
energy neutral state. Protein expression and activity of diacylglycerol
kinase δ has been shown to be decreased in type 2 diabetic subjects
and normalized upon correction of hyperglycemia [53]. This kinase is
104 V. Aas et al. / Biochimica et Biophysica Acta 1812 (2011) 94–105thought to be involved in the metabolic switch between lipid and
glucosemetabolism andmight play a role in themetabolic inﬂexibility
seen in type 2 diabetes. Other enzymatic changes and protein
modiﬁcations by HG such as glycosylations or glycations can not be
excluded and are currently under investigation.
In conclusion, chronic hyperglycemia impairs substrate oxidation in
skeletal muscle cells and reduces the metabolic switching of the cells.
This shows that hyperglycemia can induce a diabetic-resembling
phenotype in former healthy cells. The effect is most likely due to an
induced mitochondrial dysfunction or post-translational modiﬁcations.
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